Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

BACKGROUND: Therapies that maintain remission for patients with Crohn's disease are essential. Stable remission rates have been demonstrated for up to 2 years in adalimumab-treated patients with moderately to severely active Crohn's disease enrolled in the CHARM and ADHERE clinical trials....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Aliment Pharmacol Ther
Hlavní autoři: Panaccione, R, Colombel, J-F, Sandborn, W J, D'Haens, G, Zhou, Q, Pollack, P F, Thakkar, R B, Robinson, A M
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2013
Témata:
Inflammatory Bowel Disease
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4670480/
https://ncbi.nlm.nih.gov/pubmed/24134498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.12499
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky